RaDVaC Data Explorer
Antiviral database
Virus Taxonomy
← Back to Dashboard
Viekirax
NS5A inhibitor + NS3/4A protease inhibitor + CYP3A4 booster
Constituent drugs (3)
Ombitasvir
Could not render structure
View on PubChem
3D not available
Paritaprevir
Could not render structure
View on PubChem
3D not available
Ritonavir
Could not render structure
View on PubChem
Loading 3D structure...
PubChem CID 392622
Chemical Identifiers
ClinicalTrials.gov
PubMed
Clinical Development by Virus
1
Hepatitis C virus
HCV
Target: Viral NS5A + NS3/4A
Approved (other)
Preclinical
Phase 2
positive
Phase 3
positive
Approved
Japan
Approval ref (kegg.jp)
Approval ref (pmda.go.jp)
PMDA approved 2015/9/28
fixed-dose combination of Ombitasvir, Paritaprevir, Ritonavir.